Locations:
Search IconSearch
May 7, 2017/Cancer

New Survey Finds Colorectal Cancer Screening Underutilized

Tool helps physicians start the screening conversation

Carol-Burke-650p

A Cleveland Clinic colon cancer risk assessment survey found that only 36 percent of more than 27,000 respondents were adherent with current colorectal cancer (CRC) screening. In addition, less than 10 percent of respondents stated they ate five or more serving of fruit, vegetables and grains per day and only about 25 percent undertook at least 30 minutes exercise four times per week.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Colon cancer has had significant decline in the U.S. since 1980 when CRC screening was first introduced, but these results show screening for the disease — and a healthy lifestyle — appear woefully underutilized,” says Carol Burke, MD, gastroenterologist and current President of the American College of Gastroenterology.

Dr. Burke and colleagues in the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia created the online questionnaire to provide respondents information about their colorectal cancer risk, and how they can modify it by CRC screening and lifestyle and dietary changes. She and co-investigator David Dornblaser, MS, presented their findings at DDW 2017.

Our survey was created in order to increase patient awareness of their risks for CRC, explains Dr. Burke, “and the opportunities to diminish the risk, since the survey provides a call to action for patients.”

She adds: “Presenting our research to colleagues at DDW may help them target their patients with identified factors who are less likely to adhere to screening and encourage them to do so. Our next research is to determine if our tool enhanced patient’s adherence to the screening.”

Key findings

The survey, which can be found at digestive.ccf.org asks respondents about age, gender, ethnicity, height, weight, dietary factors, smoking history, physical activity level, personal and family history of CRC or polyps, and adherence to CRC screening.

In general, the results showed that those who are adherent to CRC screening are more likely to be white and female. They also have less exposure to cigarettes, eat more daily servings of a plant-based diet and exercise more than those who were not up to date with CRC screening.

Advertisement

The data also indicated that respondents with a first-degree relative with CRC and polyps were significantly more likely to adhere to screening: 35.7 percent were adherent compared with 19.4 percent of participants without an affected first-degree relative.

So far, about 29,000 people from around the world have taken the five-minute questionnaire. The mean age of the cohort was 48.1 years with 66 percent of respondents female and 34 percent male. In addition, 76.1 percent reported white ethnicity.

A call to action

After completing the survey, participants get a score of average, or above average at low, medium or high risk of CRC based on reported personal and family history of CRC, polyps or both. They also receive a family tree showing their risk and a call to action outlining what age to start screening and how frequently it should be done.

“Our hope by providing this online assessment is that individuals could take it, print out the results with the call to action and take it to their physicians to start the CRC screening conversation,” Dr. Burke says. “In turn, physicians can look at this study, get a better understanding of which individuals have decreased participation in CRC screening and target them for better utilization.”

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad